TREATMENT OPTIONS FOR TYPE 2 DIABETES IN ADOLESCENTS AND YOUTH (TODAY)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. TODAY will evaluate the safety and efficacy of three treatment regimens -- metformin alone; metformin plus rosiglitazone; and metformin plus a lifestyle program to reduce weight and increase physical activity -- by time to treatment failure based on glycemic control in children age 10-17 with Type 2 diabetes (Ty2DM). Secondary aims: compare and evaluate the arms' safety and cost- effectiveness; evaluate influence of individual and family behaviors on treatment response; and compare the arms' effects on pathophysiology of Ty2DM (beta cell function, insulin resistance, body composition, nutrition, physical activity, aerobic fitness, cardiovascular risk factors, microvascular complications, quality of life and psychological outcomes).